



Yes
You
Health

Product list

February 2026

Farmaprojects
polpharma
GROUP

Under development generics

| INN | PHARMACEUTICAL FORM | STRENGTH | REFERENCE PRODUCT |
|-------------------------------------|-----------------------------|---|---------------------------------------|
| Alimentary tract & metabolism | | | |
| Empagliflozin*/Metformin | Film - coated tablets | 5mg/500mg, 5mg/850mg, 5mg/1000mg, 12.5mg/500mg, 12.5mg/850mg, 12.5mg/1000mg | Synjardy® (Boehringer Ingelheim) |
| Allergy/Immuno | | | |
| Baricitinb* | Film - coated tablets | 2mg, 4mg | Olumiaant® (Lilly) |
| Upadacitinib | Prolonged - release tablets | 15mg, 30mg, 45mg | Rinvoq® (Abbvie) |
| Respiratory System | | | |
| Fluticasone/Vilanterol* | Inhalation powder | 92mcg/22mcg, 184mcg/22mcg | Bro Ellipta® (GSK) |
| Umeclidinium/Vilanterol* | Inhalation powder | 55mcg/22 mcg | Anoro Ellipta® (GSK) |
| Fluticasone/Umeclidinium/Vilanterol | Inhalation powder | 100mcg/74.2mcg/62.5mcg, 200mcg/74.2mcg/62.5mcg | Trelegy Ellipta® (GSK) |
| Cardiology | | | |
| Finerenone* | Film - Coated Tablets | 10mg, 20mg | Kerendia® (Bayer) |
| Bempedoic Acid | Film - Coated Tablets | 180mg | Nilemdo® (Esperion, Daiichi Sankyo) |
| Bempedoic Acid / Ezitimibe | Film - Coated Tablets | 180mg/10mg | Nustendi® (Esperion, Daiichi Sankyo) |
| Ramipril | Tablets | 2.5mg, 5mg, 10mg | Delix® (Sanofi) |
| Valsartan | Film - coated tablets | 40mg, 80mg, 160mg, 320mg | Diovan® (Novartis) |
| Valsartan/Hydrochlorothiazide | Film - coated tablets | 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, 320mg/25 mg | Codiovan® (Novartis) |
| Anti-infectives for systemic use | | | |
| Avibactam/Ceftazidime | Powder for Injection | 500mg/2g | Zavicefta® (Pfizer) |
| Short RNA (Oligonucleotide) | | | |

*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

| | | | |
|------------|------------------------|---|--------------------|
| Nusinersen | Solution for injection | 12 mg/5ml vial (2.4mg/ml) | Spinraza® (Biogen) |
| Inclisiran | Solution for injection | 284 mg/1.5 mL prefilled syringe (189 mg/mL) | Leqvio® (Novartis) |

Central Nervous System

| | | | |
|------------|-----------------------|---|----------------------------------|
| Cenobamate | Film – coated tablets | 12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg | Ontozry® (SK Biopharmaceuticals) |
|------------|-----------------------|---|----------------------------------|

Available

| INN | PHARMA CEUTICA L FORM | STRENGTH | REFERENCE PRODUCT | LACTOSE FREE | STABILITY | SHELF LIFE |
|-----|-----------------------------|----------|----------------------|-----------------|-----------|------------|
|-----|-----------------------------|----------|----------------------|-----------------|-----------|------------|

Alimentary tract & metabolism

| | | | | | | |
|-------------------------------|-----------------------|--------------------------|--------------------------------------|-----|--|--|
| Dapagliflozin* / Metformin | Film – coated tablets | 5mg/850mg, 5mg/1000mg | Xigduo® (AstraZeneca) | Yes | II: available IVa: ext. from b IVb: available | 36 months 36 months |
| Dapagliflozin* | Film – coated tablets | 5mg, 10mg | Forxiga® (AstraZeneca) | Yes | II: available IVa: ext. from b IVb: available | 36 months 36 months |
| Empagliflozin* | Film – coated tablets | 10mg, 25mg | Jardiance® (Boehringer Ingelheim) | Yes | II: available IVa: ext. from b IVb: available | 36 months 36 months – Not store above 30 oC |
| Linagliptin* | Film – coated tablets | 5mg | Trajenta® (Boehringer Ingelheim) | Yes | II: available IVa: ext. from b IVb: available | 36 months 36 months |
| Orlistat | Hard capsules | 120mg | Xenical® (Roche) | Yes | II: available IVb: not available | 24 months |
| Orlistat OTC | Hard capsules | 60mg | Alli® (GSK) | Yes | II: available IVa: not available IVb: not available | 24 months |
| Sitagliptin* | Film – coated tablets | 25mg, 50mg, 100mg | Januvia® (Merck) | Yes | II: available IVa: not available IVb: available | 36 months |

*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

| | | | | | | |
|----------------------------|-----------------------------|----------------------------|---------------------|-----|--|-----------|
| Sitagliptin*/ Metformin | Film – coated tablets | 50mg/850mg, 50mg/1000mg | Janumet® (Merck) | Yes | II: available IVa: not available IVb: available | 24 months |
|----------------------------|-----------------------------|----------------------------|---------------------|-----|--|-----------|

Anti-infectives for systemic use

| | | | | | | |
|-----------|---------|------------------------|----------------|-----|--|-----------|
| Aciclovir | Tablets | 200mg, 400mg, 800mg | Zovirax® (GSK) | Yes | II: available IVa: not available IVb: not available | 36 months |
|-----------|---------|------------------------|----------------|-----|--|-----------|

Antineoplastic & Immunomodulating Agents

| | | | | | | |
|-------------|-----------------------------|---------------------|----------------------|-----|--|-----------------------|
| Apremilast* | Film – coated tablets | 10mg, 20mg, 30mg | Otezla® (Celgene) | Yes | II: available IVa: not available IVb: not available | 18 months (target 36) |
|-------------|-----------------------------|---------------------|----------------------|-----|--|-----------------------|

Blood & Blood forming organs

| | | | | | | |
|--------------|-----------------------------|----------------------------|-------------------------------------|-----|--|-----------|
| Apixaban* | Film – coated tablets | 2.5mg, 5mg | Eliquis® (Bristol- Myers Squibb) | No | II: available IVa: ext. from b IVb: available | 36 months |
| Rivaroxaban* | Film – coated tablets | 2.5mg, 10mg, 15mg, 20mg | Xarelto® (Bayer) | No | II: on-going IVa: ext. from b IVb: on- going | 24 months |
| Rivaroxaban* | Capsules | 10mg, 15mg, 20mg | Xarelto® (Bayer) | No | II: available | 24 months |
| Ticagrelor* | Film – coated tablets | 60mg, 90mg | Brilique® (AstraZeneca) | Yes | II: available IVa: ext. from b IVb: available | 36 months |

Cardiovascular System

| | | | | | | |
|--------------------------|--|---|---|-----|--|-----------|
| Ramipril / Indapamide | Hard capsules (IR dosage form) | 5mg/2.5mg, 10mg/2.5mg, 5mg/1.25mg, 10mg/1.25mg | New combination | No | II: available | 36 months |
| Hydrochlorothi azide* | Tablets | 12.5mg, 25mg, 50mg | Esidrex® (Novartis) | No | II: available IVa: not available IVb: not available | 60 months |
| Ramipril / Amlodipine | Hard capsules | 5mg/5mg, 5mg/10mg, 10mg/5mg, 10mg/10mg | Tritace® /Ramipril (Sanofi) & Norvasc®/Amlod ipine (Pfizer) | Yes | II: available IVa: not available IVb: not available | 36 months |

*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

| | | | | | | |
|--------------------------|-----------------------|--|---------------------------------|-----|--|-----------|
| Rosuvastatin | Film – coated tablets | 5mg, 10mg, 20mg | Crestor® (AstraZeneca) | No | II: available IVa: (12 months) IVb: not available | 36 months |
| Telmisartan / Amlodipine | Bilayered Tablets | 40mg / 5mg, 40mg / 10mg, 80mg / 5mg, 80mg / 10mg | Twynsta® (Boehringer Ingelheim) | Yes | II: available IVa: ext. from b IVb: available | 36 months |

Dermatologicals

| | | | | | | |
|-------------|-----|--|-------------------------|-----|--|-----------|
| Dimetindene | Gel | 1mg /g (20g), 1mg /g (30g), 1mg /g (50g) | Fenistil(TM) (Novartis) | Yes | II: available IVa: ext. from b IVb: available | 36 months |
|-------------|-----|--|-------------------------|-----|--|-----------|

Genito-Urinary System & Sex Hormones

| | | | | | | |
|------------|-----------------------|------------------------|---------------------|----|--|-----------|
| Tadalafil* | Film – coated tablets | 2.5mg, 5mg, 10mg, 20mg | Cialis® (Eli Lilly) | No | II: available IVa: ext. from b IVb: available | 48 months |
|------------|-----------------------|------------------------|---------------------|----|--|-----------|

Musculoskeletal System

| | | | | | | |
|------------------------|-----------------------|-------------|-------------------------------------|---|-----------|--|
| Paracetamol/ Ibuprofen | Film – coated tablets | 500mg/200mg | Nurofen Ultima® (Reckitt Benckiser) | II: available IVa: on-going IVb: on-going | 36 months | |
|------------------------|-----------------------|-------------|-------------------------------------|---|-----------|--|

Nervous System

| | | | | | | |
|-------------------------|----------------------------------|----------------------------------|--------------------------|-----|--|--|
| Dimethyl Fumarate | Gastro – resistant hard capsules | 120mg, 240mg | Tecfidera® (Biogen Idec) | Yes | II: on-going IVa: ext. from b IVb: on-going | 36 months / do not store above 30oC (zone II) 24 months / do not store above 30oC (zone IVb) |
| Memantine hydrochloride | Film – coated tablets | 10mg, 20mg | Ebixa® (Lundbeck) | No | II: available IVa: available IVb: no ext. from a | 36 months |
| Quetiapine | Film – coated tablets | 25mg, 100mg, 150mg, 200mg, 300mg | Seroquel® (AstraZeneca) | No | II: available IVa: available IVb: available | 36 months |

Respiratory System

| | | | | | | |
|---------------------------------------|----------------------|---|-------------------------------|-----|--|-------------------------------------|
| Xylomethazolin e/ Dexpanthenol OTC | Nasal spray solution | 1.0mg / 50mg / ml (10ml), 0.5mg / 50mg / ml (10 ml) | Nasic(TM) (Cassella-med) | Yes | II: available IVa: ext. from b IVb: available | 24 months (0.5mg) 36 months (1.0mg) |
| Glycopyrronium | Inhalation powder | 44mcg | Seebri Breezhaler® (Novartis) | No | II: available | 24 months |

*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

| | | | | | | |
|------------------------------|-------------------|-------------|--------------------------------|-----|-------------------------------------|-----------|
| Glycopyrronium / Indacaterol | Inhalation powder | 43mcg/85mcg | Ultibro Breezhaler® (Novartis) | No | II: available IVb: on-going | 24 months |
| Vitamins & Minerals | | | | | | |
| Cholecalciferol (Vitamin D3) | Soft capsule | 20.000 IU | N/A | Yes | II: available IVa: not available | 36 months |

*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.



FARMAPROJECTS SAU
Carrer Provença 392, 6ª Planta
08025 Barcelona (Spain)
Phone +34 93 508 05 00
email: sales@farmaprojects.com

www.farmaprojects.com

